These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 3839754)

  • 21. [A pharmacokinetic study on high-dose methotrexate administration--the effects of volume changes of parenteral solutions on the elimination rate].
    Yoshioka S; Tsukamoto T; Nakano M; Oka S; Nakano M; Norimatsu H
    Gan To Kagaku Ryoho; 1994 Jan; 21(1):97-102. PubMed ID: 8291921
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A phase I and pharmacology study of continuous-infusion low-dose methotrexate administration.
    Lokich JJ; Curt G
    Cancer; 1985 Nov; 56(10):2391-4. PubMed ID: 4042071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The protein binding and elimination of methotrexate after intravenous infusions in cancer patients.
    Paxton JW
    Clin Exp Pharmacol Physiol; 1982; 9(3):225-34. PubMed ID: 7140004
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Theoretically required urinary flow during high-dose methotrexate infusion.
    Sasaki K; Tanaka J; Fujimoto T
    Cancer Chemother Pharmacol; 1984; 13(1):9-13. PubMed ID: 6733846
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study.
    Frankel LS; Wang YM; Shuster J; Nitschke R; Doering EJ; Pullen J
    J Clin Oncol; 1983 Dec; 1(12):804-9. PubMed ID: 6583318
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Active transport of methotrexate from cerebrospinal fluid in humans.
    Bode U; Magrath IT; Bleyer WA; Poplack DG; Glaubiger DL
    Cancer Res; 1980 Jul; 40(7):2184-7. PubMed ID: 7388786
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High-dose methotrexate: pharmacokinetics in children and young adults.
    Raude E; Oellerich M; Weinel P; Freund M; Schrappe M; Riehm H; Poliwoda H
    Int J Clin Pharmacol Ther Toxicol; 1988 Jul; 26(7):364-70. PubMed ID: 3209285
    [TBL] [Abstract][Full Text] [Related]  

  • 28. What can clinicians learn from therapeutic studies about the treatment of acute oral methotrexate poisoning?
    Chan BS; Dawson AH; Buckley NA
    Clin Toxicol (Phila); 2017 Feb; 55(2):88-96. PubMed ID: 28084171
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia.
    Csordas K; Hegyi M; Eipel OT; Muller J; Erdelyi DJ; Kovacs GT
    Anticancer Drugs; 2013 Feb; 24(2):189-97. PubMed ID: 23187460
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early recognition of patients with decreased methotrexate clearance following high-dose methotrexate infusion therapy.
    Ikeda H; Kihira K; Kuwata N; Arai S; Kimura Y; Miyake K; Kitaura T; Fujimura K; Kuramoto A; Fukuchi H
    Hiroshima J Med Sci; 1996 Jun; 45(2):57-62. PubMed ID: 8810132
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics of methotrexate in children with acute lymphocytic leukemia.
    Najjar TA; al Fawaz IM
    Chemotherapy; 1993; 39(4):242-7. PubMed ID: 8325125
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Investigation on individualized adjustment of target range of high-dose methotrexate].
    Hua Y; Zhao WH; Lu XT; Yang LH; Lu W
    Zhonghua Er Ke Za Zhi; 2008 Mar; 46(3):203-8. PubMed ID: 19099710
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A comparative study on the pharmacokinetics of methotrexate in a dose range of 0.5 g to 33.6 g/m2 in children with acute lymphoblastic leukemia.
    Borsi JD; Moe PJ
    Cancer; 1987 Jul; 60(1):5-13. PubMed ID: 3472638
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Methotrexate-vindesine association in the treatment of head and neck cancer influence of vindesine on methotrexate's pharmacokinetic behavior.
    Lena N; Imbert AM; Pignon T; Favre R; Meyer G; Cano JP; Carcassonne Y
    Cancer Chemother Pharmacol; 1984; 12(2):120-4. PubMed ID: 6697425
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A specific HPLC assay to determine the pharmacokinetics of methotrexate in patients.
    Chen ML; McGuire WP; Lad TE; Chiou WL
    Int J Clin Pharmacol Ther Toxicol; 1984 Jan; 22(1):1-6. PubMed ID: 6698654
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Renal excretion and pharmacokinetics of methotrexate and 7-hydroxy-methotrexate following a 24-h high dose infusion of methotrexate in children.
    Winograd B; Lippens RJ; Oosterbaan MJ; Dirks MJ; Vree TB; van der Kleijn E
    Eur J Clin Pharmacol; 1986; 30(2):231-8. PubMed ID: 3709652
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of combination chemotherapy, duration of methotrexate administration, and patient's age on methotrexate pharmacokinetics.
    Lokiec F; Poirier O; Gisselbrecht C; Marty M; Boiron M; Najean Y
    Cancer Chemother Pharmacol; 1982; 9(3):165-8. PubMed ID: 7160052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical pharmacology of intrathecal methotrexate. I. Pharmacokinetics in nontoxic patients after lumbar injection.
    Bleyer WA; Dedrick RL
    Cancer Treat Rep; 1977 Jul; 61(4):703-8. PubMed ID: 577895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetics of methotrexate following intravenous and intraventricular administration in acute lymphocytic leukemia and non-Hodgkin's lymphoma.
    Ettinger LJ; Chervinsky DS; Freeman AI; Creaven PJ
    Cancer; 1982 Nov; 50(9):1676-82. PubMed ID: 6956429
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Therapeutic drug monitoring of methotrexate in cerebrospinal fluid after systemic high-dose infusion in children: can the burden of intrathecal methotrexate be reduced?
    Niemann A; Mühlisch J; Frühwald MC; Gerss J; Hempel G; Boos J
    Ther Drug Monit; 2010 Aug; 32(4):467-75. PubMed ID: 20571463
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.